Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have an advanced, spreading, or inoperable solid tumour cancer (the specific type depends on which group within the trial a person is assigned to)
- People who have a recent tumour biopsy available, or who are able to provide a suitable tissue sample before or at the start of the screening process
- People whose tumour has a specific genetic change (mutation) in a gene called PI3Kα (the exact mutation type required depends on the trial group)
- People who are 18 years of age or older at the time of signing the consent form
- People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale called the ECOG scale — meaning the person is fully active or able to carry out light activity (confirm with trial site)
- People whose liver, kidneys, and other organs are functioning well enough to meet the trial's requirements
Who may not be able to join:
- People who have been diagnosed with a different type of cancer (either a solid tumour or a blood cancer) within the past 2 years
- People who currently have brain or spinal cord spread of their cancer that is causing symptoms
- People who have diabetes that is not well controlled, based on specific blood sugar or insulin use measures (confirm with trial site for exact thresholds)
- People who have previously been treated with a type of cancer drug that targets the PI3K, AKT, or mTOR pathways — though there may be some exceptions (confirm with trial site)
- People who have received cancer treatment — either standard or experimental — within approximately 14 days or longer before starting the trial (a specific calculation applies; confirm with trial site). Note: some hormone-based therapies may not require a break in treatment depending on the trial group
- People who still have significant side effects remaining from previous cancer treatments that have not returned to near-normal levels, with the exception of hair loss or nerve-related symptoms in the hands or feet
- People who have had radiation therapy within 14 days before the trial treatment would begin
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Phone: 1-317-615-4559
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants who experience at least 1 Dose Limiting Toxicity (DLT); Proportion of participants who experience at least 1 DLT during the first 28 days of treatment; Objective response rate (ORR) defined as the percentage of participants with partial response or complete response based on RECIST 1.1; Incidence of TEAEs/SAEs ≥ grade 2; Frequency of TEAEs according to CTCAE v5.0 criteria
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.